AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats ...
Net Product Revenue of $5.4 Million for Fourth-Quarter 2025, with >200 Enrollment Forms at the End of December Operationally Seamless Phase 2/3 Study of Atumelnant for the Treatment of ACTH-Dependent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results